Abstract:Lost or damaged cells in tissues and organs can be replaced by transplanting therapeutically competent cells. This approach requires methods that effectively manipulate cellular identities and properties to generate sufficient numbers of desired cell types for transplantation. These cells can be generated by reprogramming readily available somatic cells, such as fibroblasts, into induced pluripotent stem cells (iPSCs), which can replicate indefinitely and give rise to any somatic cell type. This reprogramming can be achieved with genetic methods, such as forced expression of pluripotency-inducing transcription factors (TFs), which can be further improved, or even avoided, with pharmacological agents. We screened chemical libraries for such agents and identified small molecules that enhance TF-mediated pluripotency induction in somatic cells. We also developed cocktails of small molecules that can functionally replace combinations of TFs required to induce pluripotency in mouse and human somatic cells. Importantly, we devised and established a general strategy to develop effective pharmacological cocktails for specific cellular reprogramming processes. In the search for useful small molecules, we also discovered and characterized previously unknown mechanisms pertinent to cellular reprogramming. A more direct method to access scarce cells for cell transplantation is transdifferentiation, which uses combinations of cell-type specific TFs to reprogram fibroblasts into the target somatic cell types across lineage boundaries. We created an alternative strategy for cellular transdifferentiation that epigenetically activates somatic cells by pairing temporal treatment with reprogramming molecules and tissue-specific signaling molecules to generate cells of multiple lineages. Using this cell-activation and signaling-directed (CASD) transdifferentiation paradigm, we converted fibroblasts into a variety of somatic cells found in major organs, such as the heart, brain, pancreas, and liver. Specifically, we induced, isolated, and expanded (long-term) lineage-specific progenitor cells that can give rise to a defined range of cell types relevant to specific tissues or organs. Transplanting these progenitor cells or their progeny was therapeutically beneficial in animal models of diseases and organ damage. Importantly, we developed chemically defined conditions, without any genetic factors, that convert fibroblasts into cells of the cardiac and neural lineages, further extending the realm of pharmacological reprogramming of cells. Continuously advancing technologies in pharmacological reprogramming of cells may benefit and advance regenerative medicine. The established pharmacological tools have already been applied to enhance the processes of cellular reprogramming and improve the quality of cells for their clinical applications. The rapidly increasing number of readily available bioactive chemical tools will fuel our efforts to reprogram cells for transplantation therapies.

A Combination Weighting Algorithm using Relative Entropy for Document Clustering

In situ reprogramming of cardiac fibroblasts into cardiomyocytes in mouse heart with chemicals

Small Molecules Enable Cardiac Reprogramming of Mouse Fibroblasts with a Single Factor, Oct4.

Conversion of Mouse Fibroblasts into Cardiomyocytes Using A Direct Reprogramming Strategy

Regulation of cardiac fibroblasts reprogramming into cardiomyocyte‐like cells with a cocktail of small molecule compounds

Conversion of Human Fibroblasts into Functional Cardiomyocytes by Small Molecules

Direct Reprogramming of Mouse Fibroblasts to Neural Progenitors

Mouse Cardiomyocytes Generated from Fibroblasts with One Pluripotency Factor and Four Small Molecules

Differentiation of Reprogrammed Mouse Cardiac Fibroblasts into Functional Cardiomyocytes

Recent advances and future prospects in direct cardiac reprogramming

Direct in Vivo Reprogramming with Non-Viral Sequential Targeting Nanoparticles Promotes Cardiac Regeneration.

Direct differentiation of rat skin fibroblasts into cardiomyocytes

Direct Reprogramming of Human Fibroblasts Toward the Cardiomyocyte Lineage

Sall4 and Myocd Empower Direct Cardiac Reprogramming From Adult Cardiac Fibroblasts After Injury

Pharmacological Reprogramming of Somatic Cells for Regenerative Medicine.

Pharmacological Reprogramming of Fibroblasts into Neural Stem Cells by Signaling-Directed Transcriptional Activation

Chemical Enhancement of in Vitro and in Vivo Direct Cardiac Reprogramming.

Improving Cardiac Reprogramming for Heart Regeneration in Translational Medicine

Abstract 210: Reprogramming Mouse Fibroblasts Into Cardiac Progenitor Cells Using Crispr Technique Targeting Endogenic Genes

Direct Reprogramming of Human Fibroblasts Toward a Cardiomyocyte-Like State.

Pharmacologically inducing regenerative cardiac cells by small molecule drugs